FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas.

abstract：:This article features the case study of a 32-year-old female patient who had undergone surgery to remove a cervical spine tumor and who later developed cervical esophagus necrosis secondary to the erosion caused by an osteosynthesis 13 years after her prosthetic cervical surgery. Barium swallow did not show anything a...

journal_title：Thoracic cancer

authors： Hernández Hernández JR,Navarro Barlés G,López-Tomassetti Fernández EM,Vega Benítez V,Núñez Jorge V

更新日期：2013-02-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in microwave ablation (MWA) ...

journal_title：Thoracic cancer

authors： Guo R,Li Y,Bie Z,Li B,Li X

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:The abundance of tumor infiltrating CD8 T cells is an important parameter for antitumor effect of PD-1/PD-L1 immune checkpoint inhibitors, which is less in epidermal growth factor receptor (EGFR) mutation than wild-type non-small cell lung cancer (NSCLC). The mechanism still requires further study. METHODS:...

journal_title：Thoracic cancer

authors： Zhao C,Su C,Li X,Zhou C

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:This study was conducted to investigate the gene expression profiles associated with thymoma to better understand the molecular mechanism underlying the pathogenesis of thymoma. METHODS:Eight patients with thymomas (type A, AB, B1, and B2) and four controls with thymic cysts were analyzed using microarray p...

journal_title：Thoracic cancer

authors： Meng FJ,Wang S,Zhang J,Yan YJ,Wang CY,Yang CR,Guan ZY,Wang CL

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:The combination of EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy is thought to increase treatment efficacy in non-small-cell lung cancer (NSCLC). This study investigated the efficacy and potential mechanisms of different combined modes of icotinib plus pemetrexed in EGFR-mutant lung adenocarcinoma ...

journal_title：Thoracic cancer

authors： Cui J,Zhang Y,Su D,Li T,Li Y

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Increasing evidence has demonstrated that circular RNAs (circRNAs) may play an important role in oncogenesis and tumor development; however, their role in lung adenocarcinoma (LUAD) remains unclear. We identified the differentially expressed circRNAs in LUAD and investigated the potential mechanisms for canc...

journal_title：Thoracic cancer

authors： Li S,Sun X,Miao S,Lu T,Wang Y,Liu J,Jiao W

更新日期：2018-08-01 00:00:00

abstract：BACKGROUND:Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non-small cell lung cancer (NSCLC). There is a lack of high-level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literatur...

journal_title：Thoracic cancer

authors： Song W,Di S,Liu J,Fan B,Zhao J,Zhou S,Chen S,Dong H,Yue C,Gong T

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:This study aimed to evaluate the characteristics of active anti-cancer treatment (AAT) compared with best supportive care (BSC) in elderly patients with advanced non-small cell lung cancer (NSCLC). METHODS:A retrospective analysis of 144 patients, aged 70 or older, with stage IIIb/IV NSCLC from 672 patients...

journal_title：Thoracic cancer

authors： Kim JH,Ryu MS,Ryu YJ,Lee JH,Shim SS,Kim Y,Chang JH

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:The aim of this study was to evaluate the cytotoxic and antitumor activity of spider venom (SV). METHODS:Cell proliferation and cytotoxicity were determined by 3 H-methyl thymidine incorporation ([3 H]-TDR) assay. DNA fragmentation and cell cycle kinetics were analyzed by FACS. In vivo inhibition of tumor s...

journal_title：Thoracic cancer

authors： Gao L,Zhang J,Liu X,Zhao M,Li L,Liu X,Zhao B

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:We investigated the effect of micro-RNA 24 (miR-24) and WWOX on non-small cell lung cancer (NSCLC) cell proliferation and migration in vitro and in vivo. METHODS:We performed bioinformatics analysis and 3' untranslated region luciferase assay to investigate the direct target of miR-24. Proliferation, apopto...

journal_title：Thoracic cancer

authors： Wang XH,Gan CZ,Xie JY

更新日期：2018-12-01 00:00:00

abstract：BACKGROUND:The study was conducted to compare the clinicopathological characteristics, survival outcomes, and metastatic patterns between pulmonary large cell neuroendocrine carcinoma (LCNEC) and other non-small cell lung cancer (ONSCLC), and to identify the prognostic factors of LCNEC. METHODS:Data of patients diagno...

journal_title：Thoracic cancer

authors： Yang Q,Xu Z,Chen X,Zheng L,Yu Y,Zhao X,Chen M,Luo B,Wang J,Sun J

更新日期：2019-04-01 00:00:00

abstract：:ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...

journal_title：Thoracic cancer

authors： Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen G

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). METHODS:Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two gro...

journal_title：Thoracic cancer

authors： Nie K,Zhang Z,You Y,Zhuang X,Zhang C,Ji Y

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Vagus nerve and recurrent laryngeal nerve (RLN) injury are not rare complications of lung cancer surgery and can cause lethal consequences. Until now, no optimal method other than paying greater attention during surgery has been available. METHODS:Four patients underwent lung surgery that involved RLN or va...

journal_title：Thoracic cancer

authors： Li H,Hu Y,Huang J,Yang Y,Xing K,Luo Q

更新日期：2018-05-01 00:00:00

abstract：:Fundamental treatment for papillary thyroid carcinoma (PTC) involves total or subtotal thyroidectomy. Iodine-131 ((131)I) is routinely utilized to target remnant thyroid cancer and metastasis after thyroidectomy. The effectiveness of other therapeutic modalities remains unsatisfactory; thus, these patients have a poor...

journal_title：Thoracic cancer

authors： Wang HJ,Yao JM,Zhang ZW,Zhao JY,Shang HX,Liao L,Dong JJ

更新日期：2015-11-01 00:00:00

abstract：:After sternal tumor resection, reconstruction of chest wall defects is still a challenging part of thoracic surgery. Three-dimensional (3D)-printed titanium alloy prosthesis implants provide an effective solution. The bionic bone trabecular micropore structure, which is beneficial to the human body, increases stabilit...

journal_title：Thoracic cancer

authors： Wang W,Liang Z,Yang S,Feng Q,Nie X,Su G,Yuan W,Han Y

更新日期：2020-11-01 00:00:00

abstract：BACKGROUND:Advanced non-small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. However, outcomes have gradually improved after the introduction of novel immunotherapies, including immune checkpoint inhibitors (ICIs). Although programmed death-ligand 1 (PD-L1) expression in tumor tissues is a known...

journal_title：Thoracic cancer

authors： Katakura S,Kobayashi N,Hashimoto H,Kamimaki C,Tanaka K,Kubo S,Nakashima K,Teranishi S,Manabe S,Watanabe K,Horita N,Hara Y,Yamamoto M,Kudo M,Piao H,Kaneko T

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:CalliSpheres are drug-eluting beads used for tumor artery embolization, with clinical benefits in a number of cancer types. The aim of the study was to examine the clinical benefits and complications of patients with stage II-IV lung cancer treated with CalliSpheres drug-eluting beads for embolization versus...

journal_title：Thoracic cancer

authors： Shang B,Li J,Wang X,Li D,Liang B,Wang Y,Han X,Dou W,Chen G,Shang J,Jiang S

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:Breast cancer (BC) is a common cancer in women worldwide. Emerging evidence has indicated that circular RNA hsa-circ_0007255 (circ_0007255) is a prognostic mediator in BC progression. However, the functional role of circ_0007255 needs to be determined. METHODS:The expression of circ_0007255, microRNA (miR)-...

journal_title：Thoracic cancer

authors： Jia Q,Ye L,Xu S,Xiao H,Xu S,Shi Z,Li J,Chen Z

更新日期：2020-03-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) activate host antitumor immunity to kill tumor cells. However, ICI therapy may be accompanied by a series of immunotherapy-related adverse effects (irAEs) caused by activated autoreactive T cells. Glucocorticoids are the mainstream therapy for irAEs. However, the usage, dosage and c...

journal_title：Thoracic cancer

authors： Wang H,Zhou J,Guo X,Li Y,Duan L,Si X,Zhang L

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:Plasmid construction of small fragments of interest (such as insertion of small fragment marker genes, expression of shRNA, siRNA, etc) is the basis of many biomolecular experiments. Here, we describe a method to clone short DNA into vectors by polymerase chain reaction (PCR), named one-step PCR cloning. Our...

journal_title：Thoracic cancer

authors： Tao CC,Yang Y,Li F,Qiao L,Wu Y,Sun XD,Zhang YY,Li CL

更新日期：2020-11-01 00:00:00

abstract：:In the past decade, a dramatic shift has been witnessed in cancer therapy in China. Although traditional cytotoxic chemotherapy still remains the treatment of choice for many malignancies, targeted therapies are now a component of treatment for many types of cancer, including lung cancer. As molecular target agents ar...

journal_title：Thoracic cancer

authors： Wang Y,Sun Y

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:Despite recent advances in treating non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK-positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK-positive NSCLC. METHODS:Between 2011 and 2018, a total of 14 ALK-positive NSCLC pat...

journal_title：Thoracic cancer

authors： Heo JY,Park C,Keam B,Ock CY,Kim M,Kim TM,Kim DW,Kim SH,Kim YJ,Lee JS,Heo DS

更新日期：2019-11-01 00:00:00

abstract：BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...

journal_title：Thoracic cancer

authors： Zuo J,Zhao M,Fan Z,Liu B,Wang Y,Li Y,Lv P,Xing L,Zhang X,Shen H

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Currently, there are no standard regimens for metastatic breast cancer patients (MBC) who have failed ≥ 3 chemotherapy treatments. The aim of this study was to assess whether weekly low-dose bevacizumab-based regimens were well tolerated and would improve efficacy in MBC patients who had failed numerous ther...

journal_title：Thoracic cancer

authors： Zhai X,Hong R,Fan Y,Yuan P,Wang J,Sang D,Chen J,Zhao C,Ou K,Ma F,Xu B

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:Achaete-scute homolog 1 (ASCL1) is a basic helix-loop-helix transcription factor and is essential in the differentiation of neuroendocrine cells and neural tissues. ASCL1 is frequently overexpressed in small cell lung cancer (SCLC) and plays a crucial role in the pathogenesis of SCLC. METHODS:This study was...

journal_title：Thoracic cancer

authors： Kim JH,Lee SY,Choi JE,Do SK,Lee JH,Hong MJ,Kang HG,Lee WK,Shin KM,Jeong JY,Choi SH,Lee YH,Seo H,Yoo SS,Lee J,Cha SI,Kim CH,Park JY

更新日期：2020-01-01 00:00:00

abstract：:Acquired respiratory-digestive tract fistulas occur with abnormal communication between the airways and digestive tract, causing the interflow of gas and liquid. Despite advances in surgical methods and the development of multimodal therapy in recent years, patients with acquired respiratory-digestive tract fistulas c...

journal_title：Thoracic cancer

authors： Wang H,Ke M,Li W,Wang Z,Li H,Cong M,Zeng Y,Chen L,Lai G,Xie B,Zhang N,Li W,Zhou H,Wang X,Lin D,Zhou Y,Zhang H,Li D,Song X,Wang J,Wu S,Tao M,Sha Z,Tan Q,Han X,Luo L,Ma H,Wang Z

更新日期：2018-11-01 00:00:00

abstract：:Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertin...

journal_title：Thoracic cancer

authors： Cheng Y,Yu Q,Xiong Y,Guo C,Nie L

更新日期：2021-01-12 00:00:00

abstract：:Tyrosine kinase inhibitors are used as first-line treatment for non-small cell lung cancer (NSCLC) patients harboring driver mutations in EGFR, ALK, ROS1, and BRAF. Currently, standard molecular testing approaches help identify single genes for such targetable driver mutations in NSCLC; however, next-generation sequen...

journal_title：Thoracic cancer

authors： Onozawa H,Saito H,Sunami K,Kubo T,Yamamoto N,Kasajima R,Ohtsu T,Hiroshima Y,Kanamori H,Yokose T,Miyagi Y

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:The prognostic values of preoperative neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) have been previously described. This study assessed the prognostic values of other pretreatment complete blood cell parameters in...

journal_title：Thoracic cancer

authors： Yuan C,Li N,Mao X,Liu Z,Ou W,Wang SY

更新日期：2017-07-01 00:00:00